| ISIN | LU2851595475 |
|---|---|
| Valor Number | 136503228 |
| Bloomberg Global ID | |
| Fund Name | Swisscanto (LU) Equity Fund Sustainable Healthy Longevity BT |
| Fund Provider |
Swisscanto Fondsleitung AG
Zurich E-Mail: fonds@swisscanto.ch |
| Fund Provider | Swisscanto Fondsleitung AG |
| Representative in Switzerland | Swisscanto Fondsleitung AG |
| Distributor(s) | Schweizerische Kantonalbanken |
| Asset Class | Equities |
| EFC Category | |
| Distribution Policy | Accumulation |
| Home Country | Luxembourg |
| Issuing Condition | The fund does not charge any issuing commission and/or fees (units are issued at the NAV) |
| Redemption Condition | The fund does not charge any redemption commission and/or fees (units are redeemed at the NAV) |
| Investment Strategy *** | The total commitments of the fund may not amount to more than 210% as a result of the use of derivatives (max. 100%) and temporary borrowing (max. 10%). |
| Peculiarities |
| Current Price * | 95.95 EUR | 15.12.2025 |
|---|---|---|
| Previous Price * | 95.20 EUR | 12.12.2025 |
| 52 Week High * | 104.42 EUR | 30.01.2025 |
| 52 Week Low * | 88.08 EUR | 08.04.2025 |
| NAV * | 95.95 EUR | 15.12.2025 |
| Issue Price * | ||
| Redemption Price * | ||
| Closing Price * | ||
| Indicative Minimum Price | ||
| Fund Assets *** | 95,277,285 | |
| Unit/Share Assets *** | 19,700 | |
| Trading Information SIX | ||
| YTD Performance | -2.85% |
31.12.2024 - 15.12.2025
31.12.2024 15.12.2025 |
|---|---|---|
| YTD Performance (in CHF) | -3.32% |
31.12.2024 - 15.12.2025
31.12.2024 15.12.2025 |
| 1 month | +0.09% |
17.11.2025 - 15.12.2025
17.11.2025 15.12.2025 |
| 3 months | +7.15% |
15.09.2025 - 15.12.2025
15.09.2025 15.12.2025 |
| 6 months | +5.08% |
16.06.2025 - 15.12.2025
16.06.2025 15.12.2025 |
| 1 year | -3.77% |
16.12.2024 - 15.12.2025
16.12.2024 15.12.2025 |
| 2 years | -4.05% |
27.08.2024 - 15.12.2025
27.08.2024 15.12.2025 |
| 3 years | - | - |
| 5 years | - | - |
| Equity Participation Rate in % | 90.54 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Share of Total Fund Assets in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Real Estate Rate in % | 0.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ADDI | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ADDI Date | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Johnson & Johnson | 4.11% | |
|---|---|---|
| Edwards Lifesciences Corp | 4.03% | |
| Pfizer Inc | 3.72% | |
| Thermo Fisher Scientific Inc | 3.36% | |
| IQVIA Holdings Inc | 3.34% | |
| Eli Lilly and Co | 3.28% | |
| CVS Health Corp | 3.10% | |
| AstraZeneca PLC | 3.07% | |
| Lonza Group Ltd | 2.96% | |
| Welltower Inc | 2.88% | |
| Last data update | 30.11.2025 | |
| TER | 1.13% |
|---|---|
| TER date | 31.03.2025 |
| Performance Fee *** | |
| PTR | |
| Max. Management Fee *** | 1.60% |
| Ongoing Charges *** | 1.13% |
|
SRRI ***
|
|
| SRRI date *** | 30.11.2025 |